Abstract
Biologic efficacy for severe asthma varies depending on age of asthma onset and inflammatory phenotype. This post hoc analysis assessed the effect of tezepelumab in patients with severe, uncontrolled asthma with childhood-onset and current allergic or non-eosinophilic disease and adult-onset and current eosinophilic or non-allergic disease using pooled data from the phase 2b PATHWAY and phase 3 NAVIGATOR studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
